This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- 5-methyl-2'-fluoroarauracil F-18
- DrugBank Accession Number
- DB14913
- Background
5-methyl-2'-fluoroarauracil F-18 is under investigation in clinical trial NCT02809690 (18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for 5-methyl-2'-fluoroarauracil F-18 (DB14913)
- Weight
- Average: 259.224
Monoisotopic: 259.083384194 - Chemical Formula
- C10H13FN2O5
- Synonyms
- 18F-FMAU
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- J932A2CDQO
- CAS number
- 241144-93-4
- InChI Key
- GBBJCSTXCAQSSJ-MSYRQUNGSA-N
- InChI
- InChI=1S/C10H13FN2O5/c1-4-2-13(10(17)12-8(4)16)9-6(11)7(15)5(3-14)18-9/h2,5-7,9,14-15H,3H2,1H3,(H,12,16,17)/t5-,6+,7-,9-/m1/s1/i11-1
- IUPAC Name
- 1-[(2R,3S,4R,5R)-3-(¹⁸F)fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
- SMILES
- CC1=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2[18F])C(=O)NC1=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 9240285
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Active Not Recruiting Diagnostic Neoplasms of the Prostate 1 0 Active Not Recruiting Diagnostic Anatomic Stage IV Breast Cancer AJCC v8 / Brain Metastases / Clinical Stage IV Cutaneous Melanoma AJCC v8 / Glioma / Malignant Brain Neoplasm / Metastatic Breast Carcinoma / Metastatic Colon Carcinoma / Metastatic Kidney Carcinoma / Metastatic Lung Carcinoma / Metastatic Melanoma / Pathologic Stage IV Cutaneous Melanoma AJCC v8 / Prognostic Stage IV Breast Cancer AJCC v8 / Stage IV Colon Cancer AJCC v8 / Stage IV Lung Cancer AJCC v8 / Stage IV Renal Cell Cancer AJCC v8 / Stage IVA Colon Cancer AJCC v8 / Stage IVA Lung Cancer AJCC v8 / Stage IVB Colon Cancer AJCC v8 / Stage IVB Lung Cancer AJCC v8 / Stage IVC Colon Cancer AJCC v8 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 87.7 mg/mL ALOGPS logP -0.72 ALOGPS logP -1.1 Chemaxon logS -0.47 ALOGPS pKa (Strongest Acidic) 10.1 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 99.1 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 55.23 m3·mol-1 Chemaxon Polarizability 23.17 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at May 20, 2019 14:34 / Updated at June 12, 2020 16:53